INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | |
|---|---|---|
Oct. 12, 2018 |
Aug. 20, 2018 |
|
| Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | ||
| Aggregate purchase price, value | $ 236,000 | |
| Aggregate purchase price, Shares | 20,000 | |
| cash paid for acquisition | $ 10,000 | |
| Therakine, Ltd. [Member] | ||
| Patent acquired | $ 15,200 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|